Literature DB >> 11841241

11 Beta-hydroxysteroid dehydrogenase type 1 from human liver: dimerization and enzyme cooperativity support its postulated role as glucocorticoid reductase.

Edmund Maser1, Bernhard Völker, Jutta Friebertshäuser.   

Abstract

11Beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD 1) is a microsomal enzyme that catalyzes the reversible interconversion of receptor-active 11-hydroxy glucocorticoids (cortisol) to their receptor-inactive 11-oxo metabolites (cortisone). However, the physiological role of 11beta-HSD 1 as prereceptor control device in regulating access of glucocorticoid hormones to the glucocorticoid receptor remains obscure in light of its low substrate affinities, which is in contrast to low glucocorticoid plasma levels and low Kd values of the receptors to cortisol. To solve this enigma, we performed detailed kinetic analyses with a homogeneously purified 11beta-HSD 1 from human liver. The membrane-bound enzyme was successfully obtained in an active state by a purification procedure that took advantage of a gentle solubilization method as well as providing a favorable detergent surrounding during the various chromatographic steps. The identity of purified 11beta-HSD 1 was proven by determination of enzymatic activity, N-terminal amino acid sequencing, and immunoblot analysis. By gel-permeation chromatography we could demonstrate that 11beta-HSD 1 is active as a dimeric enzyme. The cDNA for the enzyme was cloned from a human liver cDNA library and shown to be homologous to that previously characterized in human testis. Interestingly, 11beta-HSD 1 exhibits Michaelis-Menten kinetics with cortisol and corticosterone (11beta-dehydrogenation activity) but cooperative kinetics with cortisone and dehydrocorticosterone (11-oxoreducing activity). Accordingly, this enzyme dynamically adapts to low (nanomolar) as well as to high (micromolar) substrate concentrations, thereby providing the fine-tuning required as a consequence of great variations in circadian plasma glucocorticoid levels.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11841241     DOI: 10.1021/bi015803t

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  11 in total

1.  Mutations of key hydrophobic surface residues of 11 beta-hydroxysteroid dehydrogenase type 1 increase solubility and monodispersity in a bacterial expression system.

Authors:  Alexander J Lawson; Elizabeth A Walker; Scott A White; Timothy R Dafforn; Paul M Stewart; Jonathan P Ride
Journal:  Protein Sci       Date:  2009-07       Impact factor: 6.725

Review 2.  Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.

Authors:  David Czock; Frieder Keller; Franz Maximilian Rasche; Ulla Häussler
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

3.  Th2 cytokine-induced upregulation of 11beta-hydroxysteroid dehydrogenase-1 facilitates glucocorticoid suppression of proasthmatic airway smooth muscle function.

Authors:  Aihua Hu; Sumbul Fatma; Jing Cao; Judith S Grunstein; Gustavo Nino; Yael Grumbach; Michael M Grunstein
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-02-27       Impact factor: 5.464

Review 4.  11β-hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action.

Authors:  Karen Chapman; Megan Holmes; Jonathan Seckl
Journal:  Physiol Rev       Date:  2013-07       Impact factor: 37.312

Review 5.  11β-hydroxysteroid dehydrogenases: A growing multi-tasking family.

Authors:  Elise P Gomez-Sanchez; Celso E Gomez-Sanchez
Journal:  Mol Cell Endocrinol       Date:  2021-02-17       Impact factor: 4.102

6.  Substrate binding process and mechanistic functioning of type 1 11β-hydroxysteroid dehydrogenase from enhanced sampling methods.

Authors:  Angelo D Favia; Matteo Masetti; Maurizio Recanatini; Andrea Cavalli
Journal:  PLoS One       Date:  2011-09-23       Impact factor: 3.240

7.  Epigenetic effects of prenatal stress on 11β-hydroxysteroid dehydrogenase-2 in the placenta and fetal brain.

Authors:  Catherine Jensen Peña; Catherine Monk; Frances A Champagne
Journal:  PLoS One       Date:  2012-06-26       Impact factor: 3.240

8.  Green tea and one of its constituents, Epigallocatechine-3-gallate, are potent inhibitors of human 11β-hydroxysteroid dehydrogenase type 1.

Authors:  Jan Hintzpeter; Claudia Stapelfeld; Christine Loerz; Hans-Joerg Martin; Edmund Maser
Journal:  PLoS One       Date:  2014-01-03       Impact factor: 3.240

Review 9.  Multifaceted Control of GR Signaling and Its Impact on Hepatic Transcriptional Networks and Metabolism.

Authors:  Stine M Præstholm; Catarina M Correia; Lars Grøntved
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-08       Impact factor: 5.555

Review 10.  A Sweet Connection? Fructose's Role in Hepatocellular Carcinoma.

Authors:  Brittany Dewdney; Alexandra Roberts; Liang Qiao; Jacob George; Lionel Hebbard
Journal:  Biomolecules       Date:  2020-03-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.